Acute coronary syndromes - ticagrelor (TA236)
Fast, easy summary view of NICE guidance on 'acute coronary syndrome'
NICE recommends ticagrelor combined with low-dose aspirin for up to a year as a possible treatment for some people with acute coronary syndromes (see below).
Who can have ticagrelor?
You should be able to have ticagrelor if you:
- have a condition called ST-segment elevation myocardial infarction (major heart attack) that your cardiologist intends to treat with a procedure to widen your narrowed artery (called primary percutaneous coronary intervention)
- a condition called non-ST-segment elevation myocardial infarction (mild heart attack) or
- have been admitted to hospital with unstable angina.
If you are treated with ticagrelor because you have unstable angina, this diagnosis should be confirmed, ideally by a cardiologist, before you are offered more treatment with ticagrelor.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS.
NICE recommended ticagrelor because it works better than other treatments available on the NHS. Although it also costs more than other treatments, this was justified by the benefits it provided.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: acute coronary syndrome
This page was last updated: 08 July 2013
- Web format
- Full Guidance (PDF)
- TA236 Ticagrelor ar gyfer syndromau coronaidd acíwt: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.